Mostrando 4 resultados de: 4
Publisher
Cancers(1)
Clinical and Experimental Immunology(1)
Frontiers in Pharmacology(1)
Molecular Immunology(1)
Área temáticas
Enfermedades(4)
Farmacología y terapéutica(2)
Medicina y salud(2)
Bioquímica(1)
Microorganismos, hongos y algas(1)
Origen
scopus(4)
A view on EGFR-targeted therapies from the oncogene-addiction perspective
ArticleAbstract: Tumor cell growth and survival can often be impaired by inactivating a single oncogen - a phenomenonPalabras claves:CETUXIMAB, Combination therapy, eGFR, Erlotinib, nimotuzumab, Oncogene addiction, Targeted therapyAutores:de Leon J., Moreno E., Pérez R., Tania CrombetFuentes:scopusGangliosides, Ab1 and Ab2 antibodies. I. Towards a molecular dissection of an idiotype-anti-idiotype system
ArticleAbstract: This report is focused on the molecular basis for the interaction of a monoclonal antibody (mAb) andPalabras claves:Anti-idiotypic antibodies, H-CDR, N-Glycolyl-gangliosidesAutores:González M., López-Requena A., Mateo de Acosta C., Moreno E., Pérez R., Puchades Y., Santiago Nelson Vispo, Talavera A., Vázquez A.M.Fuentes:scopusEGFR-targeting as a biological therapy: Understanding Nimotuzumab's clinical effects
ReviewAbstract: Current clinical trials of epidermal growth factor receptor (EGFR)-targeted therapies are mostly guiPalabras claves:biological therapy, Cancer treatment, eGFR, nimotuzumab, Targeted therapyAutores:Garrido G., Moreno E., Pérez R., Tania CrombetFuentes:scopusThe anti-CD6 antibody itolizumab provides clinical benefit without lymphopenia in rheumatoid arthritis patients: results from a 6-month, open-label Phase I clinical trial
ArticleAbstract: Itolizumab is a humanized anti-CD6 monoclonal antibody (mAb) that has previously shown encouraging rPalabras claves:CD6, Clinical trial, Itolizumab, Phase I, Rheumatoid ArthritisAutores:Aira L.E., Ávila Y., Barrese Y., Carmen Elena Viada, Gómez J.A., Hernández I.M., Hernández M.V., Hernández P., López A.M., Martínez J.P., Milera J.M., Molinero C., Montero E., Moreno E., Prada D.M., Reyes Y., Rodríguez P.C., Torres R.Fuentes:scopus